Cargando…
Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures
In an analysis of risk evaluation and mitigation strategies for teratogenic drugs, Ameet Sarpatwari, Beatrice Brown and Aaron Kesselheim explore the variation in primary and secondary prevention measures.
Autores principales: | Brown, Beatrice L., Kesselheim, Aaron S., Sarpatwari, Ameet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987786/ https://www.ncbi.nlm.nih.gov/pubmed/36877723 http://dx.doi.org/10.1371/journal.pmed.1004190 |
Ejemplares similares
-
Paying Physicians to Prescribe Generic Drugs and Follow-On Biologics in the United States
por: Sarpatwari, Ameet, et al.
Publicado: (2015) -
Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage
por: Kesselheim, Aaron S., et al.
Publicado: (2017) -
Postmarket Surveillance of Medical Devices: A Comparison of Strategies in the US, EU, Japan, and China
por: Kramer, Daniel B., et al.
Publicado: (2013) -
An Uninformative Truth: The Logic of Amarin’s Off-Label Promotion
por: Hey, Spencer Phillips, et al.
Publicado: (2016) -
Physician experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use
por: Sarpatwari, Ameet, et al.
Publicado: (2023)